**Supplementary Material**

**Table 1.** Medications 3 and 6 Months After GMA Treatments

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **All** | **Lower GMA dose** | **Higher GMA dose** | **P** |
| Medication 3 months after GMA, n (%)5-ASAAZA or 6-MP PSL | 58/64 (91%)13/64 (20%)33/64 (52%) | 26/31 (84%)6/31 (19%)18/31 (58%) | 32/33 (97%)7/33 (21%)15/33 (45%) | 0.101.00.33 |
| Medication 6 months after GMA, n (%)5-ASAAZA or 6-MP PSL | 51/56 (91%)12/56 (21%)10/56 (18%) | 23/27 (85%)4/27 (15%)8/27 (30%) | 28/29 (97%)8/29 (28%)2/29 (7%) | 0.190.330.04 |

Continuous data are presented as median (IQR). Alb: serum albumin; 5-ASA: 5-aminosalicylic acid; AZA: azathioprine; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; GMA: granulocyte and monocyte adsorption; Hb: hemoglobin; 6-MP: 6-mercaptopurine; PSL: prednisolone; WBC: white blood cell counts.